ScienceDirect

Materials Today: Proceedings

Volume 51, Part 8, 2022, Pages 2539-2549

# QbD method to the formulation and development of a spironolactone immediate-release tablet with enhanced dissolving research

Jayendrasingh P. Bayas , M. Sumithra

Show more

Share Cite

https://doi.org/10.1016/j.matpr.2021.12.347

Get rights and content

## Abstract

This work aimed to improve the solubility of medication D (Spironolactone) by encapsulating it in HPCD and constructing an inclusion complexation using the kneading process. All of the formulations were put through a series of tests based on Indian pharmacopeia. All of the generated formulations were tested in vitro for drug release, and the optimal formulation was also subjected to stability tests. In terms of superior solubility profile and increase in dissolving rate, the inclusion complex created with HPCD and drug concentration of 1:1 M ratio was the best formulation among the eight batches of inclusion complex prepared. Direct compression technology produces immediate-release tablets of medication D with a quality-by-design approach. The prepared tablet in the optimal formulation has good mechanical strength, appropriate Hardness, and less than 1% friability. All batches passed the weight variation test, and the limit was kept within the Pharmacopeial standard of 5% of the total weight. The improved formulation's drug content was determined to be between 97 and 100 percent, with a disintegration time of 1 to 12 min for Spironolactone. The formulation containing Crospovidone disintegrated quickly, with medication release reaching more than 97 percent after 10 min.

## Introduction

The most common route of drug administration for medicines with systemic effects is through the mouth. When a new medicine is developed, one of the first concerns a pharmaceutical company examines is whether the drug can be taken efficiently via the oral route to achieve the desired effect [1]. Because of many independent factors governing the absorption of the drug from the gastrointestinal tract and competitive objectives, any action taken to improve the dosage forms, particularly for the prolonged release purpose, has been a challenge for formulation scientists. Modifying the solubility of the pharmacological component to prolong its release in the gastrointestinal tract, for example, may result in a reduction in the formulation's overall payload. A trial-and-error formulation process does not allow the

formulator to determine how near a specific formulation is to the ideal answer, and finding the right compromise is difficult. As a result, a quick screen is required for them to formulate effectively [2]. The BCS is a tool that formulation scientists can use to recommend a strategy for improving drug development efficiency through proper dosage form selection and bioequivalence tests, to recommend a class of immediate-release (IR) solid dosage forms for which bioequivalence can be determined using in-vitro dissolution tests, and to lay the effect of excipients(s) on drug permeability. The BCS advice considers three important factors: dissolution, solubility, and intestinal permeability, all of which influence the rate and amount of drug absorption from solid dosage forms released immediately. BCS is a concept that helps to understand the link between medication release from a product and absorption [3]. The BCS is divided into four categories, and medications are classed based on three primary bioavailability factors: dissolution, solubility, and permeability. Each BCS class has distinct properties that reflect applicability for a specific class of dosage forms as well as significance, or lack thereof, for controlled release [4]. The majority of medications have a low bioavailability, which is mostly owing to a slow dissolving rate. The drug's solubility and dissolution rate must be improved to attain better bioavailability. To improve the dissolving rate of the medications, many methods are used. The use of cyclodextrin complexation is one such method [5], [6]. Spironolactone is a low-solubility, high-permeability BCS class II drug. As a result, improving the drug's solubility is critical before moving on to the formulation of the quick release dosage form. The current research focuses on increasing solubility by inclusion complexes and then approaching cyclodextrin complexation.

## Section snippets

### 2.1Materials

We used spironolactone as the active ingredient and Hydroxy Propyl Beta Cyclodextrin (HP—CD), Crospovidone, Mannitol, Lactose monohydrate Colloidal Silicon Dioxide, Magnesium Stearate, and other medications, excipients, and chemicals in the formulation and testing of immediate-release tablets.…

### Preparation of inclusion complex

The kneading approach was used to make an inclusion complex of spironolactone and hydroxypropyl—cyclodextrin. The drug and polymer were combined in a 1:1M ratio (1:1) A tiny amount of warm water were used …

### Drug-Polymers Interaction Study (FTIR)

In accordance with the International Conference on Harmonization (ICH) recommendations Q1A (R2), expedited stability investigations were carried out. The optimized formulas (F8) have been packaged in amber glass vials separately. Optimized batches (8 samples) have been taped and stored for 1month in a stabilization chamber at room temperature and humidity (40±2°C and 75±5%HR). The samples were removed at 30days and assessed the content of drugs and drug dissolution in vitro.

In the…

### Conclusions

Using Hydroxypropyl beta-cyclodextrin, in-vitro drug release of manufactured immediate-release tablets of medication D (Spironolactone) was found to be better than a marketed product. Drug release was reported to be 99–100 percent in 30min using an improved batch (F8) with Mannitol, Lactose monohydrate 30GR diluents, and

Crospovidone XL 10 as a super disintegrant. There was no significant increase in disintegration time, assay, drug release, or relative substance after three months of…

## Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.…

Special issue articles Recommended articles

## References (19)

S.V. Sastry *et al.*
Recent technological advances in oral drug delivery–a review
Pharm. Sci. Technol. Today (2000)

J.A. Seitz *et al.*
Evaluation of the physical properties of compressed tablets I: Tablet hardness and friability
J. Pharm. Sci. (1965)

H.M. Beakawi Al-Hashemi *et al.*
A review on the angle of repose of granular materials
Powder Technol. (2018)

J.M. Airth *et al.*
Variability of uniformity of weight test as an indicator of the amount of active ingredient in tablets
J. Pharm. Sci. (1967)

L.i. Di *et al.*
Development and application of high throughput plasma stability assay for drug discovery
Int. J. Pharm. (2005)

N. Donauer *et al.*
A mini review of scientific and pharmacopeial requirements for the disintegration test
Int. J. Pharm. (2007)

M.G. Papich *et al.*
Applying biopharmaceutical classification system (BCS) criteria to predict oral absorption of drugs in dogs: challenges and pitfalls
AAPS J. (2015)

NikhilK Sachan *et al.*
Biopharmaceutical classification system: A strategic tool for oral drug delivery technology
Asian J. Pharm. (AJP): Free full text articles from Asian J. Pharm. (2009)

N. Bou-Chacra *et al.*
Evolution of choice of solubility and dissolution media after two decades of biopharmaceutical classification system

AAPS J. (2017)

There are more references available in the full text version of this article.

## Cited by (0)

View full text